Ubicare Misomol.com, Begins Supply of Eli Lilly's 'Mounjaro'

[Financial News] Ubicare announced on the 20th that it has started supplying the obesity treatment 'Mounjaro' by global pharmaceutical company Eli Lilly through the online pharmaceutical distribution platform Misomol.com. Mounjaro is currently being shipped from Misomol.com, advancing the shipping date by nearly a week compared to some platforms. Orders are also being processed, providing an environment where hospital and clinic customers can receive products faster than the market.
The market-leading electronic medical record (EMR) 'Doctor Love' and 'Doctors' are integrated with Misomol.com, which broadly distributes essential pharmaceuticals such as infusion solutions, injectables, and vaccines. Since starting the pharmaceutical distribution business in 2017, it has maintained a growth rate of over 50% annually.
This year's second-quarter transaction performance grew 180% compared to the same period last year, recording an all-time high.
In particular, in the first half of the year, the company expanded direct entry of pharmaceutical companies to supply popular products such as △GC Wellbeing's 'Lynac' △JW Pharmaceutical's 'Ducra Neoptide Expert' △Merz Korea's 'Xeomin'. In the second half, it is strengthening market penetration with pre-sales of flu vaccines and point accumulation benefits.
To commemorate the launch of Mounjaro, Misomol.com is holding a special price event for non-reimbursed obesity-related injectables, and related products can be checked through the promotional banner.
An Ubicare representative said, "With the supply of Mounjaro, the prescription options for primary medical institution customers have expanded," adding, "In the second half, we will continue to expand competitive pharmaceutical lineups and customized benefits to enhance customer satisfaction." 

vrdw88@fnnews.com Kang Joong-mo Reporter